Trelagliptin succinate
|
|
|
- CAS-Nr.
- 1029877-94-8
- Englisch Name:
- Trelagliptin succinate
- Synonyma:
- SYR-472;Trelagliptin succinat;2-[[6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioicacid;CS-924;SRY-472;SYR472 succinate;SYR-472 succinate;SYR 472 succinate;Troglitinesuccinate;SYR 111472 succinate
- CBNumber:
- CB22645151
- Summenformel:
- C22H26FN5O6
- Molgewicht:
- 475.48
- MOL-Datei:
- 1029877-94-8.mol
|
Trelagliptin succinate Eigenschaften
- storage temp.
- -20°C
- L?slichkeit
- Soluble in DMSO
- Aggregatzustand
- Powder
- Farbe
- Off-white solid
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Trelagliptin succinate Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Similar to omarigliptin,
trelagliptin succinate (XIX) is a highly selective, orally
delivered inhibitor of DPP-4 developed by Takeda Pharmaceuticals
and approved in Japan in March 2015 for the
treatment of type 2 DM. Interestingly, trelagliptin is
structurally similar to alogliptin, a DPP-4 inhibitor also
marketed by Takeda and described in our 2010 review,
differing only in the presence of a fluorine in the 5-position of
the cyanobenzyl moiety. Both trelagliptin and alogliptin are
potent inhibitors of DPP-4, with IC50s of 1.3 and 5.3 nM,
respectively. Notably, while similar drugs are dosed once
daily, trelagliptin is the first DPP-4 inhibitor approved for onceweekly
dosing. Kinetic analysis has revealed that trelagliptin is a
substrate-competitive, reversible, slow-binding inhibitor (t1/2 for
dissociation = ca. 30 min) of DPP-4, although the dissociation
time is insufficient to explain its long-acting effects. In a phase
III trial, once-weekly trelagliptin (100 mg) showed similar
efficacy and safety to once-daily alogliptin (25 mg) in patients
with type 2 DM inadequately controlled by diet and exercise.
The medicinal chemistry discovery of trelagliptin and
alogliptin as well as reviews of this class of compounds
have been published.
Verwenden
Trelagliptin succinate (SYR-472) is a selective, long acting dipeptidyl peptidase-4 (DPP-4) inhibitor. An antidiabetic agent.
Orally active DPP-4 inhibitor that produces clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. SYR472 has a long duration of action and is well tolerated in clinical studies.
Clinical Use
Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor used for the treatment of type 2 diabetes mellitus. Trelagliptin (as the salt Trelagliptin succinate) was approved for use in Japan in March 2015. Takeda, the company that developed Trelagliptin, chose to not get approval for the drug in the USA and EU.
Trelagliptin succinate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Trelagliptin succinate Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 437)Lieferanten
1029877-94-8()Verwandte Suche:
- Trelagliptin Succinate (SYR-472)
- SYR 111472 succinate
- SYR-472 succinate
- SYR-472 Trelagliptin succinat
- Trelagliptin succinate(SRY-472)
- Trelagliptin succinate
SYR 111472 succinate
- SRY-472
- Telagliptin Succinate
- Trelagliptin succinate, >=98%
- Butanedioic acid, compd. with 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (1:1)
- (R)-2-((6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-f
- Trelagliptin Succinate API
- Trelagliptin (succinate)
- SYR 472 succinate
- SYR472 succinate
- Triglitastat succinate
- (R)-2-[[6-(3-Amino-1-piperidyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydro-1-pyrimidinyl]methyl]-4-fluorobenzonitrile Succinate
- Trelagliptin succinate high quality Cas number：1029877-94-8
- CS-924
- SYR-472 SUCCINATE; SYR472 SUCCINATE; SYR 472 SUCCINATE
- Trelagliptin succinate - SYR 111472 succinate | SYR 472
- TrelChemicalbookagliptinsuccinate
- Trelagliptin Impurity 81
- SYR-472 succinate. Trelagliptin
- Trelagliptin succinate ISO 9001：2015 REACH
- Troglitinesuccinate
- relagliptin succinate
- Troxagliptin succinate
- Trelagliptin succinat
- Trogliptin succinate
- Benzoicacid,4-hydroxy-3,11-dimethoxy-
- 2-amino-1-(8-bromophenyl)ethanol
- 2-[[6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioicacid
- SYR-472
- 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2, ,butanedioic acid
- chloro-bis-methylsulfanyl-borane
- Tragliptin succinate
- Trelagliptin Impurity 35 1/4Succinate
- Troagliptin succinate
- Trelagliptin succinate, 10 mM in DMSO
- 1029877-94-8
- 1029877-94-0
- 29877-94-8
- C18H20FN5O2C4H6O4
- C22H26FN5O6
- Trelagliptin
- Inhibitors
- antidiabetic
- API
- 1029877-94-8
